IVF for beginners: 15 steps and topics, from first tests to embryo transfer

An IVF cycle is not a single procedure. It is a chain of separate medical steps, and each one has its own purpose, its own medicines and its own decisions. A patient who understands that sequence before the first appointment can follow what a clinic is doing and why. That patient can also ask sharper questions along the way.

In vitro fertilization means fertilizing eggs with sperm in a laboratory rather than inside the body. An embryo that develops from that process is then placed in the uterus. The practice involves blood tests, ultrasound scans, daily injections, a short procedure under sedation or anesthesia, several days of laboratory work and a carefully timed transfer. Each stage depends on the one before it.

This piece approaches IVF for beginners as a set of building blocks. It starts with what the treatment is, where it came from and the reasons doctors commonly recommend it. It then moves through the fertility tests that usually come first and the hormone injections that prompt the ovaries to grow several follicles. After that come the medicines that stop eggs from being released too early and the trigger shot that sets the timing for egg retrieval.

The middle of the list covers what happens in the lab. That includes how eggs are fertilized, either by placing them with sperm or by injecting a single sperm into each mature egg. It also covers how embryos are grown and graded over several days. Two more slides explain the main types of preimplantation genetic testing and the difference between fresh and frozen embryo transfer.

The final slides deal with transfer day and the wait for a pregnancy test. They also cover the main risks and side effects, the role age plays in the chance of success and the parts that make up the cost of a cycle. The cost slide notes that insurance coverage in the U.S. varies by state and employer plan.

These 15 slides are a selection of steps and topics, not a complete account of fertility care. Protocols differ between clinics and between patients, and a fertility specialist sets the plan for any individual case. Each slide is written to stand on its own. A reader can go straight to the stage that matters most. The terms used here, from gonadotropins to vitrification, are the same ones a clinic is likely to use.

Illustration: Quartz

IVF stands for in vitro fertilization, a treatment in which eggs are fertilized by sperm in a laboratory rather than inside the body. A resulting embryo is then placed in the uterus, where it can implant and develop into a pregnancy.

The name describes the method. "In vitro" is Latin for "in glass," a reference to the laboratory dishes where eggs and sperm are brought together. The opposite term, "in vivo," means "within the living" and describes processes that happen inside the body. Fertilization, the joining of an egg and a sperm, is the step that IVF moves out of the body. The stages before it prepare and collect the eggs. The stages after it return an embryo to the uterus.

That sequence is why IVF is described as a cycle. Eggs are collected first. They then spend several days in the lab, where fertilization takes place and embryos begin to grow. The last stage is a transfer, when an embryo is placed back in the uterus.

The first baby born through IVF was Louise Brown. She arrived on July 25, 1978, in Oldham, England. Her birth demonstrated that an embryo created outside the body could result in a live birth.

Two researchers developed the method behind her birth. Robert Edwards was a physiologist, a scientist who studies how the body functions. Patrick Steptoe was a gynecologist, a doctor who specializes in the female reproductive system. The work drew on both fields. The laboratory side involved handling eggs, sperm and embryos outside the body. The clinical side involved collecting eggs from a patient and placing an embryo in the uterus.

Edwards received the 2010 Nobel Prize in Physiology or Medicine. The award came more than three decades after Louise Brown was born.

The 1978 principle still defines IVF. Later laboratory techniques were built onto that same sequence rather than replacing it. Intracytoplasmic sperm injection, or ICSI, and preimplantation genetic testing are two examples.

Illustration: Quartz

IVF is commonly recommended for five medical situations: blocked or damaged fallopian tubes, severe male-factor infertility, endometriosis, diminished ovarian reserve and unexplained infertility. People also use it to build families with donor eggs or donor sperm, or when they want embryos genetically tested.

Tubal problems are a direct physical barrier to conception. In natural conception, egg and sperm usually meet inside a fallopian tube. When both tubes are blocked or damaged, that meeting point is unavailable. IVF works around the problem. Egg and sperm are joined in a laboratory dish, and the embryo is placed directly in the uterus.

Severe male-factor infertility describes cases where a semen sample shows very few sperm, sperm that move poorly or sperm with abnormal shapes. In the lab, an embryologist can bring sperm into direct contact with each egg. That removes the long journey sperm would otherwise need to make through the reproductive tract.

Endometriosis is a condition in which tissue similar to the uterine lining grows outside the uterus. It can cause scarring and inflammation in the pelvis, sometimes involving the ovaries and tubes. IVF is one of the treatment routes doctors discuss when the condition is linked to trouble conceiving.

Diminished ovarian reserve means the ovaries hold fewer eggs than expected for a person's age. IVF aims to collect several eggs in a single cycle rather than the one egg typically released each month.

Unexplained infertility is the diagnosis given when standard testing finds no clear cause. For these patients, IVF lets the clinic see whether eggs fertilize and how early embryos develop. Ordinary testing cannot show either of those things.

Not every IVF patient has a fertility diagnosis. Single people and same-sex couples often use the process with donor eggs or donor sperm. A single woman or a female couple may pair eggs with donor sperm. A male couple needs donor eggs and a gestational carrier to carry the pregnancy.

Some people turn to IVF mainly because they want embryos genetically tested before transfer. That usually applies when a family carries a known inherited condition. Testing can only be done on embryos created outside the body. IVF is therefore the required first step.

Illustration: Quartz

Before an IVF cycle begins, a typical fertility workup includes a semen analysis, an ovarian reserve check, a pelvic ultrasound and a hysterosalpingogram. Together, these tests show where a fertility problem may lie and help a clinic plan treatment.

The ovarian reserve check usually has two parts. The first is the anti-Müllerian hormone blood test, often shortened to AMH. Small follicles in the ovaries produce this hormone. Its level in the blood gives an indirect estimate of how many eggs remain.

The second part is the antral follicle count. A clinician uses a transvaginal ultrasound to count the small, fluid-filled follicles visible in each ovary. These are the follicles that could respond to fertility medicines during a treatment cycle.

Neither result measures egg quality. AMH and the antral follicle count are more useful for estimating how the ovaries may respond to stimulation than for predicting whether a pregnancy will happen. Clinics often read the two results side by side when planning medicine doses.

The pelvic ultrasound looks at the uterus and ovaries themselves. It can reveal fibroids, polyps or ovarian cysts. Some of these findings can affect whether an embryo is likely to implant or how treatment proceeds.

A hysterosalpingogram, or HSG, is an X $TWTR-ray test of the uterus and fallopian tubes. A contrast dye is passed through the cervix while X-ray images are taken. If the dye flows freely out of the tubes, they are open. If the dye does not pass through, a tube may be blocked. The images also outline the shape of the uterine cavity.

The semen analysis covers the male partner or sperm provider. A lab examines a sample for sperm count, for movement, known as motility, and for shape, known as morphology. These results can shape a later decision about how eggs are fertilized in the lab.

A workup is not one fixed list. Depending on a person's medical history, a clinic may add or skip tests. The results help determine whether IVF is the right next step and how a cycle would be set up.

Illustration: Quartz

Ovarian stimulation uses daily injections of gonadotropins to encourage several follicles in the ovaries to grow at once. This phase usually lasts roughly one to two weeks. The clinic tracks it closely and adjusts doses along the way.

A follicle is a small, fluid-filled sac in the ovary that holds a developing egg. In a typical unmedicated menstrual cycle, the body brings one follicle to maturity and releases a single egg. IVF aims for more than one. More follicles mean more eggs can be collected. More eggs give the laboratory more chances to produce an embryo.

Gonadotropins are hormones that act on the ovaries. The injectable versions used in IVF contain follicle-stimulating hormone, often shortened to FSH. Some products also carry luteinizing hormone activity, known as LH activity, while others contain FSH alone. The choice between them is part of the treatment plan a fertility doctor draws up for each patient.

Most of these medicines are given as small injections under the skin. Many patients give the shots to themselves at home, or a partner gives them, after the clinic's nursing staff demonstrates the technique. The injections are usually taken around the same time each day.

Monitoring is the other half of this stage. Patients return to the clinic for transvaginal ultrasound scans, which let the care team count the growing follicles and measure their size. Blood tests track estradiol, a form of estrogen that rises as follicles develop.

Those two measurements together show how the ovaries are responding. If follicles are growing slowly, the doctor may raise the dose. If the response looks stronger than intended, the dose may come down. Visits are often scheduled every few days. They can become more frequent as the follicles get larger.

The monitoring results also tell the clinic when the follicles are close to ready. That reading determines when stimulation ends and the next medication step begins.

Illustration: Quartz

Most IVF medication plans include a GnRH antagonist or a GnRH agonist, a drug that stops the body from releasing eggs on its own before retrieval. The choice between these two drugs gives each protocol its name.

The drug is needed because of how the menstrual cycle works. GnRH, or gonadotropin-releasing hormone, is made in the hypothalamus, a small region at the base of the brain. It signals the pituitary gland to release luteinizing hormone. A sharp rise in luteinizing hormone, called the LH surge, makes a mature follicle release its egg.

In a natural cycle, that surge is the goal. In an IVF cycle, it is a problem. If ovulation happens before the scheduled retrieval, the eggs leave the follicles and cannot be collected. The medical team needs control over the timing instead of leaving it to the body.

GnRH antagonists work by blocking GnRH receptors on the pituitary. The effect begins within hours. That allows the drug to be added partway through a cycle rather than at its start. Cetrorelix and ganirelix are two antagonist medicines used in IVF. A plan built around one of these drugs is called an antagonist protocol.

GnRH agonists take a different route. At first they overstimulate the pituitary, causing a brief release of hormones known as a flare. With continued use, the pituitary becomes desensitized and stops responding. Leuprolide is a commonly used agonist. This shutdown takes time. For that reason, the agonist usually begins before stimulation does. In a long agonist protocol, it often starts in the second half of the previous menstrual cycle.

That difference in timing is the practical split between the two approaches. An antagonist protocol tends to involve fewer days of medication overall. A long agonist protocol involves an earlier start and a longer calendar.

Both approaches serve the same purpose. Neither drug is what makes the follicles grow. That job belongs to the gonadotropin injections given during stimulation. The role of an antagonist or agonist is to hold ovulation back until the medical team decides the eggs are ready to collect. A fertility specialist picks the protocol based on a patient's history and test results.

Illustration: Quartz

The trigger shot is a single injection that completes egg maturation once the follicles reach their target size. It contains either hCG or a GnRH agonist, and egg retrieval is scheduled for about 34 to 36 hours after it is given.

hCG stands for human chorionic gonadotropin. GnRH is short for gonadotropin-releasing hormone. Both medicines serve the same purpose at this stage of an IVF cycle. They move the eggs inside the follicles through their last phase of development so the eggs can be collected.

In a natural menstrual cycle, a surge of luteinizing hormone from the pituitary gland sets off final egg maturation and then ovulation. The trigger shot reproduces that signal on a schedule the clinic controls. hCG acts on the same receptors as luteinizing hormone. A GnRH agonist trigger works one step earlier, prompting the pituitary to release a surge of the body's own luteinizing hormone.

The decision about when to inject rests on the follicle measurements taken during stimulation. The trigger is given when the follicles have grown to the size the care team is aiming for. Patients are told a specific time to take the injection. Daily stimulation injections generally stop at this point.

The 34-to-36-hour window reflects a narrow biological target. Retrieval has to happen after the eggs finish maturing but before the follicles release them. Once eggs are released into the body, they can no longer be collected from the follicles. If retrieval comes too early, more of the eggs may still be immature.

For that reason, the trigger time and the retrieval appointment are set together. Patients who miss the dose or take it at the wrong time should contact the clinic right away. The trigger shot marks the end of the stimulation phase and the point where the cycle moves to the egg retrieval procedure.

Illustration: Quartz

Egg retrieval is the step in which a doctor collects eggs from the ovaries with a thin needle guided by transvaginal ultrasound. The patient is sedated or under anesthesia, and the procedure requires no abdominal incisions.

Retrieval depends on the medication phase that comes before it. Hormone injections have encouraged several follicles to grow, and a final trigger injection has completed the maturation of the eggs inside them. The procedure is scheduled at a fixed interval after that trigger, before the body would release the eggs on its own.

A follicle is a small sac of fluid that forms in the ovary. Each follicle can contain an egg. The goal of retrieval is to empty those sacs and collect whatever eggs they hold.

The ultrasound probe is placed in the vagina, which gives the doctor a live image of the ovaries. A long, thin needle passes through the vaginal wall and into the ovary along a path shown on the screen. The doctor steers it into one follicle at a time and draws out the fluid with gentle suction. The needle then moves to the next follicle. The process continues until each one has been drained.

This route explains why there are no abdominal incisions. The needle reaches the ovaries from inside the body. There is no cut on the skin to close or bandage.

The collected fluid goes straight to the embryology laboratory. Staff there examine it under a microscope and identify the eggs. Those eggs then move on to fertilization the same day.

Sedation or anesthesia means the patient does not stay awake and alert through the needle passes. Patients should not drive themselves home afterward because of that medication.

Cramping and light spotting are common in the hours and days after retrieval. Rare complications include bleeding and infection. The clinic provides instructions on recovery and on which symptoms to report.

Illustration: Quartz

Conventional insemination places sperm with the eggs in a lab dish and leaves fertilization to the sperm. Intracytoplasmic sperm injection, or ICSI, has an embryologist inject a single sperm directly into each mature egg.

Both methods happen after egg retrieval and before the embryos begin growing in culture. The clinic and the patient choose between them, and that choice determines what happens in the lab on retrieval day.

In conventional insemination, many sperm share the dish with each egg. One of them has to reach the egg and enter it without outside help. The lab's job is to bring eggs and sperm together under controlled conditions and then check which eggs have fertilized.

ICSI takes over that last step. The name describes the technique. "Intracytoplasmic" means inside the cytoplasm, the material that fills the egg. Working under a microscope, the embryologist picks out one sperm and places it inside the egg with a fine needle. Each egg receives its own individually chosen sperm.

ICSI does not depend on sperm reaching and entering the egg on their own. For that reason, it is widely used for male-factor infertility. That term covers cases where problems with the sperm are a main reason a couple has not conceived. Placing a sperm directly inside the egg sidesteps some of those obstacles.

The technique works only on mature eggs. An egg that has not finished maturing is not injected. As a result, the number of eggs that can go through ICSI may be smaller than the number collected at retrieval.

ICSI is the newer of the two methods. The first births from ICSI were reported in 1992 in Belgium.

For patients, the practical question is which fertilization method the clinic plans to use and why. The answer is tied to the reason IVF was recommended in the first place. It also reflects the results of the semen analysis done during the initial fertility workup.

Illustration: Quartz

After fertilization, embryos spend several days in laboratory incubators before they are transferred or frozen. Embryologists check them at two main points: day three, known as the cleavage stage, and day five or six, when a developing embryo can reach the blastocyst stage.

Embryo culture is the part of IVF that happens entirely out of sight. The incubators hold embryos in a controlled environment that stands in for conditions inside the body. Patients do not take part in this phase directly. Clinics typically update them on how the embryos are developing.

The cleavage stage takes its name from the way an embryo first grows. A single fertilized cell splits into two cells, then four, and keeps dividing. The embryo does not get larger overall during these early divisions. Its cells become smaller and more numerous. By day three, embryologists can see how evenly and steadily those divisions have happened.

A blastocyst looks very different. By day five or six, the embryo has formed a fluid-filled cavity and two distinct groups of cells. The inner cell mass is the cluster that can go on to form the fetus. The outer layer, called the trophectoderm, can go on to form the placenta.

Embryologists grade blastocysts on their appearance under the microscope. They look at how far the cavity has expanded. They also assess the inner cell mass and the outer layer. A grade describes what the embryo looks like. It does not test the embryo's genetics, and it does not guarantee a pregnancy. Clinics use grades to help decide which embryo to transfer first.

Not every fertilized egg becomes a usable blastocyst. Some embryos stop dividing early. Others keep growing but never form a blastocyst suitable for transfer or freezing. This drop-off is a normal part of IVF lab work. It is one reason the number of eggs retrieved is usually larger than the number of embryos available at the end of culture.

Some clinics transfer embryos at the cleavage stage, while others wait for blastocysts. The longer culture period gives embryologists more time to see which embryos keep developing. The choice of transfer day depends on the clinic's approach and each patient's circumstances. The care team sets it case by case.

Illustration: Quartz

Preimplantation genetic testing, or PGT, checks embryos created through IVF for genetic problems before one is chosen for transfer. It comes in three main forms: PGT-A for chromosome number, PGT-M for a specific single-gene condition and PGT-SR for structural chromosome rearrangements.

All three tests depend on a biopsy. At the blastocyst stage, an embryologist removes a few cells from the embryo's outer layer. That layer, called the trophectoderm, goes on to form the placenta rather than the fetus. The inner cluster of cells, which develops into the fetus, stays in place. The removed cells then go to a genetics laboratory for analysis.

PGT-A, where the A stands for aneuploidy, looks at whether an embryo has the expected number of chromosomes. A typical human cell carries 46 chromosomes, arranged in 23 pairs. An embryo with an extra or missing chromosome is described as aneuploid. Down syndrome, for example, results from an extra copy of chromosome 21.

PGT-M, where the M stands for monogenic, serves a narrower purpose. It is used when one or both prospective parents are known to carry a variant linked to a particular inherited condition. Cystic fibrosis and Huntington's disease are two examples. The lab builds the test around that family's specific variant. The result answers a focused question about one gene rather than surveying the whole genome.

PGT-SR, where SR stands for structural rearrangement, is aimed at people who carry a balanced translocation or an inversion. In these cases, segments of chromosomes have broken off and reattached in a different arrangement. A carrier can be healthy but still produce embryos with missing or extra genetic material. The test helps identify embryos that do not carry that imbalance.

The three tests serve different purposes. PGT-M and PGT-SR address a known risk in a specific family. PGT-A is a broader screen applied without a known family variant. How much PGT-A improves the chance of a live birth is still debated. A fertility clinic can explain how the current evidence applies to an individual patient.

Older names still appear in some clinic materials and patient forums. Testing for single-gene conditions and structural rearrangements was long grouped under preimplantation genetic diagnosis, or PGD. PGT-A was often called preimplantation genetic screening, or PGS.

Illustration: Quartz

An IVF embryo can be transferred to the uterus in the same cycle as egg retrieval, which is called a fresh transfer. It can also be frozen and transferred in a later cycle. Vitrification, an ultra-rapid freezing method, is the technique clinics use today to preserve embryos.

The difference between the two comes down to timing. In a fresh transfer, the embryo goes into the uterus within days of egg retrieval. That happens in the same treatment cycle in which the ovaries were stimulated.

In a frozen embryo transfer, often shortened to FET, the embryo is stored first. It is thawed later for transfer in a separate cycle. That cycle can begin weeks, months or years after the retrieval.

Vitrification takes its name from the Latin word for glass. The process cools an embryo so quickly that the water inside it becomes a glass-like solid instead of forming ice crystals. Avoiding ice crystals matters because they can damage an embryo's cells.

Some cycles skip a fresh transfer entirely. In a freeze-all cycle, every suitable embryo is vitrified. None is transferred until a later cycle. Clinics commonly choose this route in two situations.

The first is when preimplantation genetic testing is part of the plan. Analyzing an embryo's cells takes time. Freezing the embryo lets the patient and clinic wait for results before choosing which embryo to transfer.

The second is when conditions in the body at the end of stimulation are not ideal for a transfer. That can mean a uterine lining that has not developed as hoped. It can also mean hormone levels the clinic considers unsuitable. Delaying the transfer moves it to a separate cycle, where those conditions can be assessed again.

Frozen embryos also give patients options beyond a first attempt. If one embryo is transferred and others of good quality remain, the rest can stay in storage. They can be used for later transfers without another round of ovarian stimulation and egg retrieval.

Which approach a clinic recommends depends on the individual cycle. Testing plans, the patient's response to medication and the state of the uterine lining all factor in. The final choice is made with the treating physician.

Illustration: Quartz

Embryo transfer is the step that places an embryo inside the uterus, and it is usually done without anesthesia. A thin catheter passes through the cervix, guided by ultrasound, and releases the embryo into the uterine cavity.

The embryo has already spent several days growing in a laboratory incubator. Transfer is the moment it moves from the lab into the body.

The catheter reaches the uterus through the body's natural opening. It travels through the cervix, the narrow passage at the lower end of the uterus. No needle or incision is involved. That separates transfer day from egg retrieval, which uses a needle and sedation.

Ultrasound guidance lets the clinical team watch the catheter on a screen as it moves. The image helps them place the embryo in the uterine cavity. Anesthesia is usually not needed, so the patient is typically awake for the procedure. With no sedation to recover from, transfer day is generally less involved than retrieval day.

The same basic procedure applies whether the embryo is fresh from the current cycle or was frozen and thawed. What differs is the preparation and timing leading up to transfer day.

Progesterone support is part of this stage. The hormone supports the uterine lining, the tissue where an embryo needs to implant. Clinics give it in several forms. Some patients receive injections. Others use vaginal inserts or take capsules. The clinic chooses the form and the schedule, and that support continues through the waiting period.

The stretch between transfer and the pregnancy test is commonly called the two-week wait. The name reflects the gap before a definite answer arrives. The test that ends it measures hCG, short for human chorionic gonadotropin, a hormone produced in pregnancy.

Roughly two weeks separate transfer from that blood test. The clinic sets the exact date, and it can vary between patients and protocols. A blood measurement of hCG is what the clinic uses to confirm whether the cycle has resulted in a pregnancy.

Illustration: Quartz

The main medical risks of IVF are ovarian hyperstimulation syndrome, known as OHSS, and a pregnancy with twins or higher multiples when more than one embryo is transferred. Other possible problems include hormone side effects, ectopic pregnancy and complications from egg retrieval.

Each of these risks is tied to a particular stage of a cycle. Knowing which stage carries which risk helps patients understand what a clinic is watching for and when.

OHSS is linked to the stimulation phase. Its name describes the problem: the ovaries respond too strongly to the fertility medicines meant to make several follicles grow at once. That over-response is the reason clinics track how the ovaries are reacting during stimulation rather than leaving the medicines to run unchecked.

Hormone side effects form a separate category. The medicines used to stimulate the ovaries can cause bloating. They can also bring mood changes. These effects come from the hormones themselves, not from a needle or catheter.

Multiple pregnancy is a risk set by a decision made on transfer day. Placing more than one embryo in the uterus raises the chance of twins, triplets or more. Single embryo transfer, in which only one embryo is placed, lowers that chance. Patients decide the number of embryos to transfer together with their clinic. The multiples risk is part of that decision.

Ectopic pregnancy can also occur after IVF. In an ectopic pregnancy, the embryo implants outside the uterus instead of inside it. Placing the embryo directly in the uterus during transfer does not rule out this risk.

Egg retrieval carries its own rare risks of bleeding and infection. These belong to the retrieval procedure and are separate from hormone effects or transfer decisions.

Taken together, the risks fall into three groups. Some come from the medicines, some from the procedures and some from the number of embryos transferred.

Illustration: Quartz

Age at the time of egg retrieval is the strongest single factor in whether IVF leads to a pregnancy and birth. The chance of success in any one cycle falls as that age rises.

The key word is retrieval. What counts is how old a person was when the eggs were collected, not how old they are when an embryo is transferred. An embryo made from eggs retrieved at a younger age keeps the prospects tied to that earlier age. That holds even if the embryo is frozen and transferred years later.

That distinction shapes how some people plan. Someone who freezes eggs or embryos earlier in life is storing eggs from that younger age. Freezing does not pause aging in the rest of the body. It does fix the age of the eggs that are stored.

Donor eggs follow the same logic. When a patient uses eggs from a donor, the age that matters most for those eggs is the donor's age at retrieval, not the recipient's. This is one reason donor eggs are an option for people with diminished ovarian reserve.

Success per cycle is not the same as success over a full course of treatment. Many patients go through more than one cycle. A lower chance in a single attempt describes that attempt, not every attempt a person might make. A fertility specialist can explain how a patient's own test results and medical history sit alongside age.

In the U.S., fertility clinics report their outcomes to the Centers for Disease Control and Prevention. The Society for Assisted Reproductive Technology, known as SART, also publishes clinic data. Both present results by patient age group.

That structure matters for anyone comparing clinics. A clinic that treats more older patients may post lower overall numbers than one that treats mostly younger patients. The gap can reflect who the patients are rather than the quality of care. Comparing results within the same age group gives a fairer picture than comparing headline figures.

One question for a first consultation is how the clinic's results look for patients in the same age bracket. Another is whether those results come from fresh or frozen embryo transfers. Clinics may report the two separately.

Illustration: Quartz

The price of an IVF cycle is made up of several core parts: fertility medications, monitoring, egg retrieval, laboratory work and embryo transfer. Add-ons such as ICSI, preimplantation genetic testing and embryo storage are charged on top of that base.

Medications cover more than one stage of treatment. Ovarian stimulation relies on injectable gonadotropins, taken daily for roughly one to two weeks. Clinics adjust those doses as treatment goes on. The amount of medication can therefore differ from one patient to another. The trigger shot that finishes egg maturation is a separate drug. So is the progesterone that supports the uterine lining after transfer.

Monitoring refers to the repeated clinic visits during stimulation. Each visit typically involves a transvaginal ultrasound and a blood estradiol test. These checks let the care team track follicle growth and set the timing of the trigger shot.

Egg retrieval is a procedure in its own right. It requires sedation or anesthesia, an ultrasound-guided needle and a team to collect fluid from each follicle. Laboratory work comes next. Embryologists fertilize the eggs, grow the resulting embryos in incubators for several days and grade them. The transfer, in which a catheter places an embryo in the uterus, completes the core cycle.

Add-ons change the total depending on the treatment plan. ICSI, where an embryologist injects a single sperm into each mature egg, is a distinct lab service from conventional insemination. Preimplantation genetic testing adds an embryo biopsy as well as the genetic analysis itself. Embryo storage applies whenever embryos are frozen through vitrification and kept for later use. A frozen embryo transfer in a later cycle is also a separate step from the original retrieval.

Clinics can present these items as a single package or as individual charges. Knowing the components makes it easier to see what a given quote does and does not include.

Insurance coverage for IVF in the U.S. is not uniform. Mandates differ from state to state. The terms of an employer's health plan also shape what is covered. Two patients at the same clinic can face different out-of-pocket costs for a similar cycle as a result. Plan documents, or a direct question to the insurer, show which parts of treatment — medications, procedures, lab work or storage — fall under a specific policy.